About AM-pharma

AM-Pharma’s purpose is to save and improve the lives of patients confronted with severe medical conditions. Our initial focus is  acute kidney injury, impacting hundreds of thousands of people hospitalized each year. Our proprietary compound, ilofotase alfa, has the potential to become the first treatment for  acute kidney injury and its potential effect has been demonstrated in almost 1,000 patients in global clinical trials. We are a dedicated team driven to bring treatment options to severely ill patients, their families and specialty care professionals.

OUR MISSION

AM-Pharma strives to develop medicines for patients confronted with severe medical conditions. Our proprietary asset, ilofotase alfa, is initially being developed for the treatment of patients with acute kidney injury and has been granted FDA fast-track status. With approximately 1000 patients evaluated to date in clinical trials, ilofotase alfa has a proven safety profile and a demonstrated kidney benefit. We are a dedicated team driven to bring treatment options to severely ill patients, their families and acute care professionals.

Our investors

LATEST NEWS

AM-Pharma to Participate in Upcoming Investor Conferences

Utrecht, The Netherlands, January 5, 2022 – AM-Pharma B.V.,…

AM-Pharma Appoints Martijn Negen as VP Commercial Strategy

Utrecht, The Netherlands, 15 June 2021 – AM-Pharma B.V., an…

LATEST NEWS

AM-Pharma to Participate in Upcoming Investor Conferences

Utrecht, The Netherlands, January 5, 2022 – AM-Pharma B.V.,…

AM-Pharma Appoints Martijn Negen as VP Commercial Strategy

Utrecht, The Netherlands, 15 June 2021 – AM-Pharma B.V., an…